Peptide therapy: what it is and what the evidence shows
This page explains what is known, and not known, about peptides in orthopedic recovery. Rehabilitation comes first, and any prescription follows an in-person evaluation by a licensed provider.
What researchers study, and what is proven
Tissue repair signaling
Peptides such as BPC-157 and TB-500 are studied for effects on pathways involved in repair, including blood vessel formation and cell migration. Almost all of this work is in animals and cell cultures.
Collagen synthesis and fibroblast action
Tendons and ligaments are mostly collagen, made by fibroblast-type cells. Mechanical load is the best-established signal for that process. Some peptides are examined for effects on the same cells in the lab. Whether this helps people is unproven.
Systemic recovery and growth hormone secretagogues
Some compounds act on the growth hormone axis. They are not approved for recovery, they affect blood sugar and fluid balance, and they need monitoring. Sleep, nutrition and training load come first.
BPC-157 is the most discussed peptide for tendon and ligament injuries, and the research is mostly in animals. The evidence gap is similar for TB-500 and tissue repair. A different group, growth hormone secretagogues, acts through the pituitary and carries different risks.
None of these peptides is FDA-approved for orthopedic use. Read the guide for each compound before you decide anything.
How a physician decides
Care starts with questions and blood work, not a product list. A physician reviews your history, screens for conditions that make a peptide inappropriate, and explains the evidence, regulatory status and risks. Sometimes the answer is no. Where a prescription is appropriate, it comes from a licensed pharmacy with lot-level test results, and follow-up is scheduled.
Unlike research chemicals, medical-grade peptides come from a licensed pharmacy for a named patient. You can read what happens at a peptide consultation from history to follow-up before you book. Labs have a limited job, covered in our page on blood tests for recovery.
About the clinical team behind this page
Dr. Arnaldo Manuel Mora is Medical Director and leads clinical governance at Nova. His background is in internal and occupational medicine. He oversees diagnostic intake, baseline laboratory review and the safety standards that apply before any prescription therapy, including pharmacy sourcing and contraindication screening as described in our safety guide.
Dr. Michael D. Schreiber is an osteopathic physician. He applies osteopathic principles to musculoskeletal diagnosis and rehabilitation, looking at the whole kinetic chain when judging how a joint or tendon problem developed, and advises on how physician care and physical therapy fit together. He is a graduate of the Chicago College of Osteopathic Medicine of Midwestern University, class of 1992.
Medical disclaimer: The information on this site is for education and does not replace a consultation, diagnosis or treatment. Peptides are prescription-only at Nova, are prescribed only after an in-person physician evaluation, and are not FDA-approved for orthopedic use. Full credentials are on our physicians and clinical governance page.
Keep reading
Individual results vary and no outcome is guaranteed. Peptides discussed on this site are not FDA-approved for orthopedic use, and a physician decides after an in-person evaluation whether any is appropriate.